Ultragenyx Pharmaceutical Inc. $RARE Stock Position Decreased by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 61.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 29,679 shares of the biopharmaceutical company’s stock after selling 47,206 shares during the period. Hsbc Holdings PLC’s holdings in Ultragenyx Pharmaceutical were worth $663,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at approximately $39,000. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $56,000. Smartleaf Asset Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 43.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 751 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 26.1% in the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 549 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $66,000. Institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on RARE. Wells Fargo & Company increased their target price on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Wedbush reduced their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Guggenheim decreased their price target on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. Finally, Royal Bank Of Canada raised their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.41.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Shehnaaz Suliman sold 5,740 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 19,319 shares of company stock worth $476,837 over the last quarter. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $31.71 on Thursday. The stock has a market cap of $3.12 billion, a P/E ratio of -5.19 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a one year low of $18.29 and a one year high of $39.89. The company has a fifty day moving average price of $27.14 and a 200 day moving average price of $24.45.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The firm had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company’s revenue was down 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.57) earnings per share. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.